|
Indian Journal of Dermatology, Venereology and Leprology
Medknow Publications on behalf of The Indian Association of Dermatologists, Venereologists and Leprologists (IADVL)
ISSN: 0378-6323 EISSN: 0973-3922
Vol. 70, Num. 4, 2004, pp. 246-247
|
Indian Journal of Dermatology, Venereology, Leprology, Vol. 70, No. 4, July-August, 2004, pp. 246-247
Letter To Editor
Dexamethasone cyclophosphamide pulse therapy: Some suggestions for modifications
Gandhi Vijay, Bhattacharya SN
Department of Dermatology and Venereology, University College of Medical Sciences and GTB Hospital
Correspondence Address:A-242, Surya Nagar, Ghaziabad - 201011
vj125@rediffmail.com
Code Number: dv04083
Sir,
It was truly enlightening and educative reading the editorial on dexamethasone
pulse therapy in dermatology[1] and
the associated viewpoint by Prof. Pasricha[2] who
is widely regarded as the father of pulse therapy in India. Pulse therapy
has altered the management and outcome of autoimmune diseases in general
and pemphigus in particular. It has slowly but surely replaced the conventional
dosing schedules for administration of oral steroids. In response to
Dr. Ramam′s query (where do we go from here?), I would like to propose the following suggestions for modifications in the time tested though somewhat rigid protocol of pulse therapy:
- The total duration of treatment may be individualized according
to the severity of the disease and response to therapy. So instead
of a regimental
approach of a total of 18 months for phases II and III, we may rely on
a combination of the clinical severity index, immunofluorescence titers
and promptness of response to therapy to decide whether to shorten the
duration in quick responders and to extend it in slow responders and
smoldering cases.
- The decision to stop pulse therapy after 18 months in phase II + III can be individualized depending on the results of immunofluorescence (IF) tests. This may decrease the relapse rates. The relapse rate is 13-27% if direct IF (DIF) is negative at the end of treatment but increases to 4-100% if DIF is positive. Similarly, the relapse rate is 24% if indirect IF (IIF) is negative and increases to 57% if
IIF is positive at the end of treatment.[3],[4],[5]
- Serology by IIF can be replaced by ELISA for direct measurement
of desmoglein 1 and desmoglein 3 antibodies.
- As regards the reservations about the toxicity of cyclophosphamide,
it is the cumulative dose that increases the chances of malignancies
be it carcinoma of the bladder or hematological malignancies.[6],[7] A
mathematical calculation shows that with a daily dose of cyclophosphamide
of 50 mg in phases II and III, the cumulative dose is approximately
25 g. A simple approach to reduce the cumulative dose of cyclophosphamide
would be to omit daily administration altogether and replace it with
a
bolus dose of 500 mg every 4 weeks. The modified phase II would then
consist of bolus doses of dexamethasone (100 mg x 3 days) and cyclophosphamide
(500 mg on day 2) for 9 months. The modified phase III would consist
of
only bolus doses of cyclophosphamide 500 mg intravenously every 4 weeks
for a further 9 months instead of an oral dose of 50 mg daily. This
would reduce the cumulative dose of cyclophosphamide in phases II and
III to
9 g only.
- The bladder toxicity with bolus doses of cyclophosphamide can
be further reduced by concomitant administration of MESNA (sodium
2-mercaptoethane sulfonate) given intravenously. This is easily available
in India and is
given on the day of administration of bolus cyclophosphamide. The usual
dose is equivalent to the dose of cyclophosphamide and is given intravenously
over 15-30 minute infusions in 5 divided doses over 24 hrs. It acts
by binding to the acrolein metabolite which is implicated in causing
hemorrhagic
cystitis and the subsequent development of transitional cell carcinoma
of the bladder.
- Regarding the management of patients with fulminant disease in
whom activity is not controlled in spite of addition of interval
pulses and
daily steroids, a different approach may be the use of immunoablative
high dose cyclophosphamide without stem cell rescue. This approach
has been
utilized with success in other autoimmune diseases like systemic lupus
erythematosus, acquired aplastic anemia and more recently for paraneoplastic
pemphigus.[8],[9],[10] It
involves use of a high dose of cyclophosphamide (50 mg/kg) intravenously
to induce suppression of a clonal population of B cells followed by
administration of granulocyte colony stimulating factor (G-CSF). A
high dose of cyclophosphamide
spares the progenitor hematopoeitic stem cells in the bone marrow which
express high levels of aldehyde dehydrogenase, an enzyme causing resistance
to cyclophosphamide. However, peripheral lymphoid tissue, being susceptible,
is suppressed, with apparent clearing of pre-existing autoimmunity.
After a nadir of leucopenia at 8-12 days, there is a repopulation by
division
of stem cells from the bone marrow which have been spared. G-CSF given
during this period hastens this process. Obviously, this approach has
to be reserved for severe cases unresponsive to conventional DCP and
has to
be carried out in institutional settings under cover of broad spectrum
antibiotics and anti-candidal drugs. As G-CSF is now available in India
(Grastim©) this approach can be tried in selected cases.
- Persistent oral ulcers are usually treated with topical steroids
in a gel/orabase. An alternative approach may be to spray these lesions
directly with a steroid inhaler (budesonide or fluocinolone acetonide)
used in asthma. Apart from a rapid effect, an additional advantage
is that palatal and pharyngeal ulcers that are not accessible to topical
steroids
can be treated effectively.
I hope that the practicability of these suggestions can be tried in
different centers in order to further improve the efficacy of pulse therapy.
REFERENCES
1. | Ramam M. Dexamethasone pulse therapy in Dermatology. Indian J Dermatol Venereol Leprol 2003;69:319-22. Back to cited text no. 1 |
2. | Pasricha JS. Pulse therapy as a cure for autoimmune diseases. Indian J Dermatol Venereol Leprol 2003;69:323-8. Back to cited text no. 2 |
3. | David M, Weissman-Katzendson V, Ben chetrit A, et al. The usefulness of immunofluorescent tests in pemphigus patients in clinical remission. Br J Dermatol 1989;120:391-5. Back to cited text no. 3 |
4. | Ratnam KV, Pang BK. Pemphigus in remission: Value of negative direct immunofluoresence in management. J Am Acad Dermatol 1994;30:547-50. Back to cited text no. 4 [PUBMED] |
5. | Harman KE, Albert S, Black MM; British Association of Dermatologists. Guidelines for the management of Pemphigus vulgaris. Br J Dermatol 2003;149:926-37. Back to cited text no. 5 [PUBMED] [FULLTEXT] |
6. | Radis C, Kahl L, Baker G, Wasko MC, Cash JM, Gallatin A, et al. Effects of cyclophosphamide on the development of malignancy and on long term survival of patients with rheumatoid arthritis. Arthritis Rheumatol 1995:38:1120-7. Back to cited text no. 6 |
7. | Talar Williams C, Hijazi Y, Walther M, Linehan WM, Hallahan CW, Lubensky I, et al. Cyclophosphamide induced cystitis and bladder cancer in patients with Wegener's granulomatosis. Ann Intern Med 1996:124:477-84. Back to cited text no. 7 |
8. | Brodsky RA, Sensenbrenher LL, Jones RJ. Complete remission in severe aplastic anemia after high dose cyclophophamide without marrow transplantation. Blood 1996;87:491-4. Back to cited text no. 8 |
9. | Brodsky RA, Petri M, Smith BD, Seifter EJ, Spivak JL, Styler M, et al. Immunoablative high dose cyclophosphamide without stem cell rescue for refractorysevere autoimmune disease. Ann Intern Med 1998;129:1031-5. Back to cited text no. 9 [PUBMED] [FULLTEXT] |
10. | Nousari HC, Brodsky RA, Jones RJ, Grever MR, Anhalt GJ. Immunoablative high dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: Report of a case and review of this new therapy for severe autoimmune disease. J Am Acad Dermatol 1999:40:750-4. Back to cited text no. 10 |
Copyright 2004 - Indian Journal of Dermatology, Venereology, Leprology
|